Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 2—February 2023
Research

Incidence and Transmission Dynamics of Bordetella pertussis Infection in Rural and Urban Communities, South Africa, 2016‒2018

Fahima MoosaComments to Author , Stefano Tempia, Jackie Kleynhans, Meredith McMorrow, Jocelyn Moyes, Mignon du Plessis, Maimuna Carrim, Florette K. Treurnicht, Orienka Helferscee, Thulisa Mkhencele, Azwifarwi Mathunjwa, Neil A. Martinson, Kathleen Kahn, Limakatso Lebina, Floidy Wafawanaka, Cheryl Cohen, Anne von Gottberg, Nicole Wolter, and for the PHIRST Group
Author affiliations: University of the Witwatersrand, Johannesburg, South Africa (F. Moosa, S. Tempia, J. Moyes, M. du Plessis, M. Carrim, O. Hellferscee, C. Cohen, A. von Gottberg, N. Wolter); National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg (F. Moosa, J. Kleynhans, J. Moyes, M. du Plessis, M. Carrim, F.K. Treurnicht, O. Hellferscee, T. Mkhencele, A. Mathunjwa, C. Cohen, A. von Gottberg, N. Wolter); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Tempia, M.L McMorrow); Johns Hopkins University, Baltimore, Maryland, USA (N.A. Martinson); National Research Foundation, Pretoria, South Africa (N.A. Martinson); South African Medical Research Council, Cape Town, South Africa (N.A. Martinson, K. Kahn, L. Lebina, K. Mothlaoleng, F. Wafawanaka, A. Mathee); North-West University, Potchefstroom, South Africa (S. Piketh)

Main Article

Table 2

Incidence rate and factors associated with Bordetella pertussis incidence for 1,684 participants in the PHIRST study of respiratory infections, South Africa, 2016–2018*

Characteristic B. pertussis incidence (95% CI) Univariate analysis
Multivariable analysis
Incidence rate ratio (95% CI) p value Adjusted incidence rate ratio (95% CI) p value
Overall
0.2 (0.17–0.25)
NA
NA

NA
NA
Year
2016 0.25 (0.17–0.35) Referent NA NA
2017 0.13 (0.09–0.19) 0.53 (0.17–1.63) 0.27 NA NA
2018
0.26 (0.20–0.33)
1.04 (0.44–2.49)
0.92

NA
NA
Site
Rural 0.17 (0.13–0.22) Referent NA NA
Urban
0.24 (0.19–0.31)
1.5 (0.77–2.96)
0.23

NA
NA
Sex
M 0.23 (0.17–0.30) Referent NA NA
F
0.19 (0.15–0.24)
0.83 (0.58–1.19)
0.31

NA
NA
Age group, y
<5 0.21 (0.14–0.33) 1.41 (0.69–2.90) 0.37 1.62 (0.56–4.65) 0.37
5–14 0.27 (0.20–0.35) 1.76 (0.96–3.21) 0.09 1.73 (0.91‒3.31) 0.09
15–44 0.17 (0.12–0.24) 1.12 (0.62–2.04) 0.78 1.09 (0.59–2.00) 0.78
>45
0.15 (0.09–0.25)
Referent


Referent

HIV status
Uninfected 0.22 (0.18–0.27) Referent NA NA
Infected
0.14 (0.08–0.25)
0.64 (0.36–1.11)
0.11

NA
NA
Nutritional status†
Underweight 0·20 (0.10–0.38) 0.68 (0.28–1.66) 0.39 NA NA
Normal 0.23 (0.18–0.28) Referent NA NA
Overweight/obese
0.30 (0.21–0.43)
0.76 (0.52–1.13)
0.18

NA
NA
Underlying illness‡
No 0.20 (0.17–0.24) Referent NA NA
Yes
0.36 (0.16–0.80)
1.78 (0.68–4.70)
0.24

NA
NA
Pertussis vaccination§
Incomplete 0.91 (0.23–3.64) 4.89 (1.47–16.02) 0.01 4.48 (1.38–14.59) 0.01
Fully vaccinated 0.19 (0.11–0.32) Referent Referent
Unknown
0.20 (0.17–0.25)
1.08 (0.61–1.91)
0.78

1.32 (0.42–4.13)
0.64
Crowding¶
No 0.15 (0.11–0.21) Referent Referent
Yes 0.25 (0.20–0.31) 1.63 (0.86–3.08) 0.13 1.53 (0.78–2.97) 0.21

*Bold indicates statistical significance. Variables adjusted for in final model were age group, pertussis vaccination, and crowding. NA, not applicable; PHIRST, Prospective Household cohort study of Influenza, Respiratory Syncytial virus, and other respiratory pathogens community burden and Transmission dynamics in South Africa. †Nutritional status is based on a person’s body mass index (BMI). We defined BMI categories as follows: underweight, age <18 y weight for age or BMI <‒2 SDs of World Health Organization (WHO) Child Growth Standards; age >18 y BMI <18.5 kg/m2; overweight, age <18 y BMI >+1 and ≤+2 SD of the WHO growth standards, age ≥18 y BMI ≥25 and <30 kg/m2; obese, age <18 y BMI >+2 SD of WHO growth standards, age ≥18 y BMI >30 kg/m2. ‡Defined as self-reported history of asthma, lung disease, heart disease, stroke, spinal cord injury, epilepsy, organ transplant, immunosuppressive therapy, organ transplantation, cancer, liver disease, renal disease, or diabetes. §Collected only for children <5 y of age· Vaccine status calculate based on number of doses of vaccine received by age. ¶More than 2 persons in a household sleeping in the same room.

Main Article

Page created: November 23, 2022
Page updated: January 21, 2023
Page reviewed: January 21, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external